Fubotv earnings beat by $0.10, revenue topped estimates
Investing.com -- GoodRx Holdings, Inc. (NASDAQ:GDRX) reported second quarter earnings that fell short of analyst expectations, sending shares down 6.2% as both revenue and earnings missed Wall Street estimates.
The medication savings platform posted revenue of $203.1 million for the second quarter, up 1% YoY but below the analyst consensus of $205.87 million. Adjusted earnings per share came in at $0.09, missing analyst expectations of $0.10. The company reported net income of $12.8 million, representing a net income margin of 6.3%, compared to $6.7 million and 3.3% in the same period last year.
GoodRx’s prescription transactions revenue, its largest segment, decreased 3% to $143.1 million, driven by a 14% decline in Monthly Active Consumers. The company attributed this drop to "broader changes in the retail pharmacy landscape, including store closures, and volume reduction in one of our integrated savings programs."
"I’m excited about the meaningful progress we made during the second quarter delivering against our key initiatives that are designed to better position the Company for sustainable long-term growth," said Wendy Barnes, Chief Executive Officer and President of GoodRx.
While subscription revenue fell 7% to $20.5 million, pharma manufacturer solutions revenue showed strong growth, increasing 32% to $35.0 million compared to the prior year.
For full-year 2025, GoodRx expects revenue to increase from 2024’s $792.3 million but didn’t provide specific figures. The company forecasts Adjusted EBITDA between $265-$275 million, representing 2-6% growth over 2024.
CFO Chris McGinnis noted that the Rite Aid (NYSE:US90274J5618=UBSS) bankruptcy and volume reduction in an integrated savings program are expected to result in approximately $35-$40 million of estimated revenue loss in 2025, impacting the company’s guidance.
During the quarter, GoodRx repurchased 10.2 million shares of Class A common stock for $46.4 million, with $143.0 million remaining in its share repurchase program.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.